{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-014059","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.687691+00:00","generated_at":"2026-06-16T06:32:08.483998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evofem Biosciences FY2022 net product sales $16.8M (+104% YoY); net loss $(78.0M)","bullets":["Net product sales doubled to $16.8M in 2022 from $8.2M in 2021, driven by unit growth and promotional strategies.","Total operating expenses cut 42% to $101.0M, exceeding the stated $50M cost reduction goal.","Net loss attributable to common stockholders improved to $(78.0)M ($1.34/diluted share) from $(206.2)M ($23.63/share) in 2021.","Cash at Dec 31, 2022: $2.8M unrestricted; raised $1.8M from senior secured convertible notes in Q1 2023.","Appointed Ivy Zhang as CFO and Secretary effective April 13, 2023; targeting EBITDA break-even by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-014059","json":"https://secwatch.observer/filing/0001493152-23-014059.json","markdown":"https://secwatch.observer/filing/0001493152-23-014059.md","text":"https://secwatch.observer/filing/0001493152-23-014059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/0001493152-23-014059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:32:08.483998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f11c5be505a5827127b789999bccf4faf88a4600","claim":"Evofem Biosciences, Inc. reported the year ended December 31, 2022 results: revenue $16.8 million, net income $(78.0) million, or $(1.34) per share, EPS $(1.34) per share.","evidence_excerpt":"citric acid and potassium bitartrate), has reported financial results for the year ended December 31, 2022. Highlights include: ● Increased Phexxi net product sales 104% to $16.8 million in 2022. ● Gained Phexxi coverage for more than 22.1 million new lives since January 1, 2023. ● More than 80% of Phexxi claims are now being approved (as of February 2023, the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/0001493152-23-014059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$16.8 million"},{"label":"Net income","value":"$(78.0) million, or $(1.34) per share"},{"label":"EPS","value":"$(1.34) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}